Advancements in Cancer Vaccines

Cancer immunotherapy has transformed the treatment landscape for many malignancies over the past two decades. Therapies that harness the immune system, including checkpoint inhibitors, monoclonal antibodies and adoptive cellular therapies, have improved survival rates in diseases once considered refractory to treatment. These treatments work by enhancing the body’s natural ability to detect and destroy malignant cells, shifting oncology away from approaches that rely on chemotherapy or radiation alone.

Even with these advances, many tumors continue to evade immune detection or develop resistance to immunotherapy. As a result, researchers are increasingly exploring strategies that can more precisely train the immune system to recognize cancer cells as foreign and mount durable responses against them. Among the most promising of these approaches are cancer vaccines. Cancer vaccines aim to stimulate immune responses against tumor cells by presenting tumor-associated antigens or tumor-specific neoantigens to the immune system. Unlike traditional vaccines designed to prevent infectious diseases, cancer vaccines may be used either prophylactically by preventing infection-related cancers, or therapeutically to treat existing malignancies.¹

In recent years, advances in genomic sequencing, computational biology and messenger RNA (mRNA) technology have accelerated progress in the field of cancer vaccines. In fact, personalized cancer vaccines designed to target patient-specific tumor mutations are now entering late-stage clinical trials, with early results suggesting meaningful improvements in recurrence-free survival when used alongside immune checkpoint inhibitors.²

“Current immunotherapies successfully treat 20 percent of the deadliest cancers by unleashing the power of cancer-killing T cells,” said Elizabeth Jaffee, MD, deputy director of the Johns Hopkins Kimmel Cancer Center. “Vaccines have the potential to increase the success of these immunotherapies in the other 80 percent of deadly cancers by creating cancer-killing T cells. The last decade of scientific discoveries has propelled vaccines toward becoming the next generation of successful immunotherapies for cancer treatment and prevention.”³

Understanding the Mechanisms of Cancer Vaccines

Cancer vaccines are broadly categorized into two groups: preventive vaccines that reduce cancer risk, and therapeutic vaccines that are designed to treat established disease.

Preventive cancer vaccines represent one of the most successful applications of immunization in oncology. These vaccines target infectious pathogens known to drive malignant transformation, thereby reducing the incidence of virus-associated cancers. The most widely utilized example is the human papillomavirus (HPV) vaccine, which protects against viral strains responsible for the majority of cervical cancers, as well as a substantial proportion of anal, oropharyngeal, penile and other anogenital malignancies.⁴ Widespread HPV vaccination programs have led to marked reductions in infection rates and precancerous cervical lesions among vaccinated populations. In fact, population-level studies demonstrate that countries with high HPV vaccine uptake have observed reductions of up to 90 percent in HPV infections among vaccinated individuals.⁵ These findings underscore the substantial potential of vaccination programs to prevent cancer before it develops.

Therapeutic cancer vaccines are designed to treat established malignancies by stimulating immune responses against tumor-associated antigens or neoantigens expressed by cancer cells. In contrast to preventive vaccines, which aim to avert disease onset, these approaches seek to mobilize the immune system to recognize and eliminate existing tumors. One of the earliest and most well-characterized examples is sipuleucel-T, a dendritic cell-based immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer.¹ In this treatment approach, peripheral blood mononuclear cells are collected from the patient via leukapheresis and exposed to a fusion protein containing a prostate tumor antigen. The activated antigen-presenting cells are then reinfused, where they stimulate a T-cell-mediated immune response directed against prostate cancer cells.

Clinical trials demonstrated that sipuleucel-T improved overall survival by approximately four months compared with placebo in men with advanced prostate cancer.⁶  Although the survival rate benefit was modest, these findings provided important proof-of-concept that therapeutic cancer vaccines can yield clinically positive outcomes.

Together, these cancer vaccine approaches illustrate how immunization strategies can be adapted to different points along the disease continuum, from risk reduction to active disease management. Ongoing advances in antigen selection, vaccine platforms and immune modulation continue to refine their effectiveness and expand their potential clinical applications.

mRNA Vaccines and the Future of Precision Oncology

Messenger RNA (mRNA) technology has emerged as a leading platform for next-generation cancer vaccines. Rather than delivering tumor antigens directly, mRNA vaccines encode genetic instructions that prompt host cells to produce tumor antigens internally, triggering immune activation. One of the key advantages is that mRNA vaccines can be rapidly designed, manufactured and modified to encode multiple tumor antigens simultaneously. The success of mRNA vaccine platforms during the COVID-19 pandemic demonstrated their scalability and safety in large populations.

One of the most advanced programs involving a personalized neoantigen vaccine is the mRNA-4157/V940, a novel mRNA-based personalized cancer vaccine that encodes up to 34 patient-specific tumor neoantigens. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. A randomized KEYNOTE-942 trial assessed the efficacy of the vaccine in prolonging recurrence-free survival (RFS) in patients with resected, stages IIIB/IIIC/IIID and IV melanoma, when given in combination with pembrolizumab, the standard-of-care adjuvant therapy in this patient population. Patients were randomly assigned to receive mRNA-4157/V940 in combination with pembrolizumab or pembrolizumab alone. The vaccine was administered every three weeks for a total of nine doses, and pembrolizumab was given every three weeks for up to 18 cycles. According to the 18-month primary trial analysis, there was a 44 percent reduction in the risk of recurrence or death in patients who received both mRNA-4157/V940 and pembrolizumab, compared to those who only received pembrolizumab.²

“For many patients with stage III/IV melanoma, there is a significant risk of recurrence following surgery. As such, demonstrating the longer-term potential of intismeran autogene and pembrolizumab to reduce the risk of recurrence for certain patients with melanoma is a meaningful milestone,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.⁷

These results represent some of the first randomized clinical evidence supporting the use of personalized mRNA cancer vaccines in oncology and have prompted additional Phase III trials evaluating the approach in melanoma and other malignancies.

Emerging Non-mRNA Cancer Vaccine Platforms 

Neoantigen vaccines have emerged as a central component of precision oncology. Leveraging next-generation sequencing technologies, researchers can identify somatic mutations unique to an individual patient’s tumor. The data is then analyzed using computational algorithms to predict which mutated proteins are most likely to elicit a strong and clinically meaningful immune response. Once prioritized, these neoantigens are incorporated into personalized vaccine constructs encoding tumor-specific sequences. Upon administration, the vaccine induces T-cell responses directed against cancer cells expressing these mutations, enabling highly targeted immune-mediated tumor destruction.⁸

This approach addresses several limitations associated with earlier vaccine strategies. Because neoantigens are not expressed in normal tissues, they represent highly specific immune targets, thereby minimizing the risk of off-target toxicity while enhancing antitumor specificity. Clinical investigation of neoantigen-based vaccines is rapidly expanding across a range of malignancies, including melanoma, lung cancer, pancreatic cancer and renal cell carcinoma. Early-phase studies have demonstrated the ability of these vaccines to generate robust, polyclonal T-cell responses capable of recognizing multiple tumor-specific mutations simultaneously, supporting their potential as a versatile and adaptable therapeutic platform.

In parallel, dendritic cell-based vaccines represent another important non-mRNA cancer treatment strategy. Dendritic cells are central to immune activation, functioning as professional antigen-presenting cells that initiate and regulate T-cell responses. Therapeutic approaches in this category involve isolating dendritic cells from the patient, loading them ex vivo with tumor-associated antigens and reinfusing them to stimulate a targeted immune response. While sipuleucel-T remains the most established example of a dendritic cell vaccine, similar platforms are under active investigation in glioblastoma (brain cancer), melanoma and other solid tumors.⁹ Across numerous clinical trials in glioblastoma, dendritic cell vaccines have shown encouraging potential to extend patient survival. These results suggest that personalized, dendritic cell–based approaches may help overcome the highly immunosuppressive tumor microenvironment characteristic of brain tumors.¹⁰

Promising as they are, dendritic cell-based therapies face hurdles in broader implementation due to the complexity of individualized cell collection and processing. Researchers are therefore focused on streamlining production, improving scalability and reducing costs to make these therapies more widely accessible.

Assessing the Role of AI

Personalized cancer vaccines are designed to train patients’ immunes system to target their unique tumor. Developing them requires fine-tuning at every stage — from selecting neoantigens to engineering mRNA sequences and designing delivery systems. AI is now accelerating each step, making vaccines both faster to develop and more effective.

Deep learning models, including convolutional and recurrent neural networks and transformers, can predict how peptides bind to MHC molecules and how T cells will recognize them. Generative models optimize genetic sequences, while multitask frameworks integrate complex biological data to improve neoantigen selection and vaccine yield. Early results suggest these approaches outperform traditional methods, identifying targets more accurately and efficiently.

AI also enables truly personalized formulations. By analyzing a patient’s genomic, proteomic and immunological profile, models can predict which delivery strategies and adjuvant combinations will work best. For instance, patients with high inflammation might benefit from gentler formulations, while those with immunosuppressive tumors may require stronger adjuvants. This patient-specific tailoring helps ensure vaccines elicit the strongest possible immune response, overcoming challenges that have long limited cancer vaccine effectiveness.¹¹

Addressing the Challenges Ahead

Cancer vaccines still face significant hurdles before becoming standard in clinical care. Biological challenges include tumor immune evasion and heterogeneity, which can limit how effectively a vaccine stimulates an antitumor response. Technical obstacles arise from the complexity of designing, manufacturing and delivering highly personalized therapies in a timely and cost-effective manner. Regulatory considerations also remain a moving target, as traditional frameworks must adapt to accommodate vaccines tailored to individual patients while maintaining rigorous standards for safety, quality and efficacy.¹²

Despite these challenges, progress is accelerating. Advances in mRNA platforms, genomic sequencing and tumor immunology — supported by AI-driven insights — are enabling highly personalized vaccines that can target patient-specific mutations with remarkable precision. The future likely involves combining vaccines with checkpoint inhibitors, targeted therapies and other immunomodulators to boost efficacy and overcome tumor resistance.

As these strategies are refined and validated in larger trials, cancer vaccines have the potential to transform oncology, making treatment more precise, durable and tailored to each patient.